Allecra is focused on the treatment of Gram-negative multi drug-resistant infections

Allecra’s drug candidate, AAI101 is an extended-spectrum ß-lactamase inhibitor belonging to the penicillanic acid sulfone class that exhibits potent in vitro and in vivo activity against many resistant Gram-negative pathogens. In pre-clinical studies, AAI101 showed broader and more potent activity than tazobactam against challenge panels of resistant pathogens.1-5 AAI101’s spectrum of activity makes it particularly useful in protecting ß-lactams against hydrolysis by ESBLs, such as TEM-type, SHV-type, or CTX-M-type, as well as some carbapenemases5

The clinical development program is focused on combining AAI101 with well-established ß-lactam antibiotics in order to restore their effectiveness:

  • Cefepime/AAI101 is a combination of AAI101 and cefepime, a powerful 4th generation cephalosporin, used for the treatment of many serious hospital infections, including complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP). The combination cefepime/AAI101 is currently entering Phase 2 clinical development
  • Piperacillin/AAI101 is a combination of AAI101 and piperacillin, a broad spectrum penicillin which, combined with tazobactam, has been used for many years to treat serious hospital-acquired infections. The piperacillin/AAI101 combination has completed Phase 1 clinical development

Each of Allecra’s product candidates is designed to have a unique spectrum of activity and is clearly differentiated from current treatment options and from competitor development pipelines

1. Paul-Satyaseela M et al. Poster presented at ECCMID 2014.
2. Nordmann P et al. Poster presented at ECCMID 2014.
3. Mushtaq S et al. Poster presented at ECCMID 2014.
4. Carmelli Y et al. Poster presented at ECCMID 2014.
5. Crandon JL, Nicolau DP. Pathogens 2015;4:620-5.